Comparative bactericidal activity of four fluoroquinolones against Pseudomonas aeruginosa isolated from chronic suppurative otitis media.

Q2 Medicine BMC Ear, Nose and Throat Disorders Pub Date : 2015-10-14 eCollection Date: 2015-01-01 DOI:10.1186/s12901-015-0018-9

Katsuhisa Ikeda, Shigeki Misawa, Takeshi Kusunoki

{"title":"Comparative bactericidal activity of four fluoroquinolones against Pseudomonas aeruginosa isolated from chronic suppurative otitis media.","authors":"Katsuhisa Ikeda, Shigeki Misawa, Takeshi Kusunoki","doi":"10.1186/s12901-015-0018-9","DOIUrl":null,"url":null,"abstract":"Background: The aim of the present study was to evaluate the bactericidal activity of four new fluoroquinolones against current isolates of Pseudomonas aeruginosa from the patients with chronic suppurative otitis media (CSOM).Methods: We examined bactericidal activity of four types of fluoroquinolones, garenoxacin (GRNX), levofloxacin (LVFX), ciprofloxacin (CPFX) and sitafloxacin (STFX) against current isolates of P. aeruginosa (50 strains).Results: STFX exhibited the most potent activity of both MIC50 and MIC90, followed by CPFX, LVFX, and GRNX. The number of GRNX-resistant strains was significantly greater than those of LVFX, CPFX, and STFX (P < 0.05).Conclusion: STFX showed the most potent activity against P. aeruginosa for recent pathogens recovered from CSOM as compared with the others, suggesting that the clinical application of topical STFX would be useful to prevent the emergence of resistant mutants of P. aeruginosa.","PeriodicalId":39843,"journal":{"name":"BMC Ear, Nose and Throat Disorders","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12901-015-0018-9","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Ear, Nose and Throat Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12901-015-0018-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 10

Abstract

Background: The aim of the present study was to evaluate the bactericidal activity of four new fluoroquinolones against current isolates of Pseudomonas aeruginosa from the patients with chronic suppurative otitis media (CSOM).

Methods: We examined bactericidal activity of four types of fluoroquinolones, garenoxacin (GRNX), levofloxacin (LVFX), ciprofloxacin (CPFX) and sitafloxacin (STFX) against current isolates of P. aeruginosa (50 strains).

Results: STFX exhibited the most potent activity of both MIC50 and MIC90, followed by CPFX, LVFX, and GRNX. The number of GRNX-resistant strains was significantly greater than those of LVFX, CPFX, and STFX (P < 0.05).

Conclusion: STFX showed the most potent activity against P. aeruginosa for recent pathogens recovered from CSOM as compared with the others, suggesting that the clinical application of topical STFX would be useful to prevent the emergence of resistant mutants of P. aeruginosa.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

四种氟喹诺酮类药物对慢性化脓性中耳炎铜绿假单胞菌的抑菌活性比较。

背景:本研究的目的是评价四种新型氟喹诺酮类药物对慢性化脓性中耳炎(CSOM)患者中铜绿假单胞菌的抗菌活性。方法:检测加诺沙星(GRNX)、左氧氟沙星(LVFX)、环丙沙星(CPFX)和西他沙星(STFX) 4种氟喹诺酮类药物对铜绿假单胞菌(P. aeruginosa)现有分离株(50株)的杀菌活性。结果:STFX对MIC50和MIC90的活性最强，其次是CPFX、LVFX和GRNX。grnx耐药菌株数量明显大于LVFX、CPFX和STFX (P)。结论:STFX对铜绿假单胞菌(P . aeruginosa, P. aeruginosa, P. CSOM)近期恢复的病原菌具有最强的抗药活性，提示临床应用STFX可有效预防P. aeruginosa耐药突变体的出现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Ear, Nose and Throat Disorders Medicine-Otorhinolaryngology

CiteScore

3.30

自引率

0.00%

发文量

期刊介绍： BMC Ear, Nose and Throat Disorders is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of ear, nose and throat disorders, as well as related molecular genetics, pathophysiology, and epidemiology. BMC Ear, Nose and Throat Disorders (ISSN 1472-6815) is indexed/tracked/covered by PubMed, CAS, EMBASE, Scopus and Google Scholar.